Abstract
Autologous hematopoietic cell transplantation (auto-HCT) using melphalan is the standard of care in the management of myeloma. Auto-HCT is a safe procedure with tolerable toxicity except in Asian-Indians. We hypothesized either one or a combination of factors: (1) frailty (assessed by IMWG frailty score), (2) generic melphalan pharmacokinetic area under the curve (AUC) assessed by high-performance liquid chromatography, and (3) pharmacogenetics of glutathione S-transferase (GSTP1) assessed by Sanger sequencing, to be associated with toxicity and survival outcomes post auto-HCT. Disease response was evaluated by IMWG response criteria at day +100 post auto-HCT. Gastrointestinal (GI) toxicity, infections, hospital stay, progression-free survival (PFS) were also recorded. A total of 35 patients were evaluated over 2 years (2016â2018). Frailty, not HCT-comorbidity index correlated with GI toxicity and infections. Overall there was an 11-fold variation in melphalan AUC with a median of 27.88âmgâh/L (10.06â110.26). Patients with AUC more than the median had more GI toxicity and infections. Patients with wild-type GSTP1 polymorphism had more GI toxicity and infections. Frailty, AUC, or GSTP1 polymorphism did not impact hospitalization duration or PFS. A combination of the factors frailty, melphalan pharmacokinetics, and pharmacogenetics impacts GI toxicity and infections after auto-HCT in myeloma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jain T, Sonbol MB, Firwana B, Kolla KR, Almader-Douglas D, Palmer J, et al. High-dose chemotherapy with early autologous stem cell transplantation compared to standard dose chemotherapy or delayed transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Biol Blood Marrow Transplant .2019;25:239â47.
Dhakal B, Szabo A, Chhabra S, Hamadani M, DâSouza A, Usmani SZ, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol. 2018;4:343â50.
Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood. 1992;80:1666â72.
Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002;99:731â5.
Shaw PJ, Nath CE, Lazarus HM. Not too little, not too much-just right! (Better ways to give high dose melphalan). Bone Marrow Transplant. 2014;49:1457â65.
Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc. 2008;83:1131â8.
Kumar L, Boya RR, Pai R, Harish P, Mookerjee A, Sainath B, et al. Autologous stem cell transplantation for multiple myeloma: long-term results. Natl Med J India. 2016;29:192â9.
Bagal BP, Khattry N, Dongre A, Kanan S, Menon H, Sengar M, et al. Outcomes of autologous stem cell transplant (ASCT) in multiple myeloma from a tertiary cancer center in India. J Clin Oncol. 2012;30 15_suppl:e17003.
Malhotra P, Yanamandra U, Khadwal A, Prakash G, Lad D, Law AD, et al. Autologous stem cell transplantation for multiple myeloma: single centre experience from North India. Indian J Hematol Blood Transfus. 2018;34:261â7.
Naithani R, Dayal N, Rai R, Pathak S, Singh M. Autologous hematopoietic stem cell transplantation for multiple myeloma in India. Indian J Hematol Blood Transfus. 2018;34:564â5.
Aggarwal M, Agrawal N, Yadav N, Verma P, Ahmed R, Mehta P, et al. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Ann Hematol. 2018;97:1869â77.
Kulkarni U, Devasia AJ, Korula A, Fouzia NA, Nisham PN, Samoon YJ, et al. Use of non-cryopreserved peripheral blood stem cells is associated with adequate engraftment in patients with multiple myeloma undergoing an autologous transplant. Biol Blood Marrow Transplant. 2018;24:e31â5.
Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant .2006;38:501â6.
Blijlevens N, Schwenkglenks M, Bacon P, DâAddio A, Einsele H, Maertens J, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapyâEuropean Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol. 2008;26:1519â25.
Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068â74.
Nath CE, Shaw PJ, Trotman J, Zeng L, Duffull SB, Hegarty G, et al. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br J Clin Pharmacol. 2010;69:484â97.
Pinguet F, Joulia JM, Martel P, Grosse PY, Astre C, Bressolle F. High-performance liquid chromatographic assay for melphalan in human plasma. Application to pharmacokinetic studies. J Chromatogr B Biomed Appl. 1996;686:43â9.
Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691â5.
Common toxicity criteria for adverse events (CTCAE). https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
Kumar SK, Buadi FK, Rajkumar SV. Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing. Blood. 2019;133:652â9.
Hari PN, Majhail NS, Zhang MJ, Hassebroek A, Siddiqui F, Ballen K, et al. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2010;16:395â402.
Hong S, Rybicki L, Abounader D, Bolwell BJ, Dean R, Gerds AT, et al. Association of socioeconomic status with outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2016;22:1141â4.
Kumar L, Vikram P, Kochupillai V. Recent advances in the mangement of multiple myeloma. Natl Med J India. 2006;19:80â9.
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381:752â62.
Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, et al. The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma. Bone Marrow Transplant. 2014;49:1323â9.
Rosko AE, Huang Y, Benson DM, Efebera YA, Hofmeister C, Jaglowski S, et al. Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. J Geriatr Oncol. 2019;10:479â85.
Gay F, Engelhardt M, Terpos E, WÀsch R, Giaccone L, Auner HW, et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018;103:197â211.
Engelhardt M, Dold SM, Ihorst G, Zober A, Möller M, Reinhardt H, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. 2016;101:1110â9.
Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, et al. Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Haematologica. 2018;103:514â21.
Moreau P, Kergueris MF, Milpied N, Le Tortorec S, Mahé B, Bulabois CE, et al. A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. Br J Haematol. 1996;95:527â30.
Nath CE, Trotman J, Tiley C, Presgrave P, Joshua D, Kerridge I, et al. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. Br J Clin Pharmacol. 2016;82:149â59.
KÃŒhne A, Sezer O, Heider U, Meineke I, Muhlke S, Niere W, et al. Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. Clin Pharm Ther. 2008;83:749â57.
Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3:28â35.
Vangsted A, Klausen TW, Vogel U. Genetic variations in multiple myeloma II: association with effect of treatment. Eur J Haematol .2012;88:93â117.
Hu X, Xia H, Srivastava SK, Pal A, Awasthi YC, Zimniak P, et al. Catalytic efficiencies of allelic variants of human glutathione S-transferase P1-1 toward carcinogenic anti-diol epoxides of benzo[c]phenanthrene and benzo[g]chrysene. Cancer Res. 1998;58:5340â3.
Karaesmen E, Rizvi AA, Preus LM, McCarthy PL, Pasquini MC, Onel K, et al. Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. Blood. 2017;130:1585â96.
Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AJ, et al. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood. 2003;102:2345â50.
Dumontet C, Landi S, Reiman T, Perry T, Plesa A, Bellini I, et al. Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. Bone Marrow Transplant .2010;45:1316â24.
Schilthuizen C, Broyl A, van der Holt B, de Knegt Y, Lokhorst H, Sonneveld P Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma. Haematologica. 2007;92:277â8.
Acknowledgements
This work was funded by the Science and Engineering Research Board, Department of Science and Technology, Government of India (file number ECR/2016/000884) grant to ANP and DPL.
Author information
Authors and Affiliations
Contributions
RVN and KSK contributed equally to the manuscript. DPL, ANP, PM, and SV conceived and designed the study. RVN, DPL, PM, AK, GP, AJ, and SV were involved in patient recruitment and clinical care of the patients. KSK, ANP, SM, SA, and NV analyzed the lab data. DPL, RVN, ANP, and PM drafted the manuscript. All authors revised the manuscript and approved the final version. DPL and ANP confirm full access to the data in the study and final responsibility for the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisherâs note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Clinical trials registry of India Identifier CTRI/2018/08/015354
Rights and permissions
About this article
Cite this article
Nampoothiri, R.V., Kasudhan, K.S., Patil, A.N. et al. Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplant 54, 2088â2095 (2019). https://doi.org/10.1038/s41409-019-0631-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-019-0631-0
This article is cited by
-
Evaluation of gastrointestinal complications in Egyptian patients after autologous stem cell transplantation using melphalan-based regimens
The Egyptian Journal of Internal Medicine (2023)
-
Still learning the right way to administer melphalan in autologous transplantation
Bone Marrow Transplantation (2020)